-
Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 201...
Objective: In Norway, diagnoses from specialist health care visits, drug prescriptions, and causes of deaths are registered in compulsory health registers. We aimed to determine... -
MOESM1 of The impact of data quality and source data verification on epidemio...
Additional file 1: Table S1. Complete list of study variables with descriptions. Table S2. Overview of audit frequency by site. Figure S1. Summary of reported audit findings for... -
dedup_wf_001--db5885c320022259d45bb89a3476e54f
Table S1. List of the included studies. (DOCX 20Â kb) -
dedup_wf_001--139623b0ce6e2a116d48d741c1f77d72
Additional file 1. Questionnaire: â The prevalence of hypertension in HIV/AIDS patients on antiretroviral therapy compared with art-naĂŻve patients at the Limbe regional... -
dedup_wf_001--9b78a84bcc44eb791659848165e53e0c
Additional file 1. Descriptive summary of serum mogamulizumab pharmacokinetic parameter values for Cycle 1, single dose. Table of PK values after one dose. -
dedup_wf_001--f63c6b5138096880003b986b23101a87
SUCRA all scenarios. SUCRA ranking score of all licensed treatments of individual matches connecting both networks as well as the base case scenario containing all matches. (PDF... -
dedup_wf_001--c1c1f26acc8db86f0cd47eac5053574e
Assay variability. Intra-assay (Table S1.), inter-assay (Table S2.), inter-operator (Table S3.) and inter-site (Table S4.) variability was assessed as described in the... -
Additional file 3: of A nationwide study of multidrug-resistant tuberculosis ...
Table S2. Characteristics of non-clustered cases, including the ID displayed in Fig. 3, identified Mycobacterium tuberculosis lineage and sub-lineage, patients’ country of... -
Additional file 1: of Toward population specific and personalized treatment o...
Table S1–1. Efficacy of 7-day triple therapy in the first line treatment of the individual studies. Table S1–2. Efficacy of 10-day triple therapy in the first line treatment of... -
Economic issues to consider for gene drives
We examine four economic issues regarding gene drive applications made possible by gene editing technologies. First, whether gene drives are self-sustaining or self-limiting... -
dedup_wf_001--2516e2fafd73fe89725c228ba8a8457a
Table S4. Information on previous hospital stays of the patients. Depicts previous hospital stays of the patients, including information in which hospitals they previously...
